Teva Canada and Novartis Canada formed a partnership to ensure continued access to Mayzent (siponimod) for people in Canada living with active secondary progressive multiple sclerosis (SPMS). Teva Canada will take over the promotion, distribution, and commercialization of the oral MS therapy in Canada. The companies say…
Canada
Recommended Posts
- Ironically, cutting out coffee gave me a boost of energy
- MS Awareness Month events highlight advocacy, education, fundraising
- I’m going to be more open about my invisible scars from MS
- Having parents who smoked increases risk of pediatric MS: Study
- Ocrevus and Tysabri appear to work equally well to control relapsing MS